Study: Vaccines’ Alum Adjuvant Path to Brain Found

July 15, 2013

15 Jul (GAIA HEALTH) – A new study adds a major link in the association of aluminum adjuvants in vaccines with neurological disorders. It demonstrates the pathway along which aluminum in vaccine adjuvants is transferred from the injection site to the brain, where it persists indefinitely.  They have also identified a likely carrier and a means by which the process occurs.

The study is exhaustive, eliminating a wide array of options that might mitigate against their findings. They also focused on two groups to determine if their findings indicate that they’re at particular risk. They include newborns and people with a certain genetic variant. On top of that, the elderly may be at significantly higher risk for aluminum adjuvant-induced neurotoxic harm.  (full story at GAIA HEALTH)